Effect of leucogenenol, a thymothyroid hormone, on allograft rejection and hemolysin formation.
Recent investigations in this laboratory have established that daily treatment with leucogenenol, an enolic heterocyclic hormone synthesized by the thymus and/or thyroid, induces neonatally thymectomized mice that have accepted a skin allograft to reject this allograft in 7 to 14 days. Also, daily treatment with leucogenenol causes neonatally thymectomized mice to respond to challenge with sheep erythrocytes with the formation of normal titers of hemolysin. These results demonstrate that the hormone leucogenenol induces the development of those cells, absent in neonatally thymectomized mice, that are necessary for a normal immune response.
D000818:Animals; D000831:Animals, Newborn; D002454:Cell Differentiation; D005260:Female; D006084:Graft Rejection / Q000187:drug effects*; D006460:Hemolysin Proteins / Q000096:biosynthesis*; D007932:Leucogenenol / Q000097:blood / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008813:Mice, Inbred ICR; D013141:Spiro Compounds / Q000494:pharmacology*; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology; D013934:Thymectomy; D013950:Thymus Gland / Q000378:metabolism; D013961:Thyroid Gland / Q000378:metabolism
D006460:Hemolysin Proteins; D013141:Spiro Compounds; D007932:Leucogenenol